Health ❯ Healthcare ❯ Vaccines

COVID-19

Moderna mRNA Technology Booster Shots Vaccine Distribution Public Health Policy FDA Approvals Pfizer Vaccine Development Pfizer-BioNTech FDA Approval Vaccine Safety Vaccine Availability Vaccine Controversies Vaccine Approval Novavax Chicago Clinical Trials Adverse Events FDA Regulations Operation Warp Speed Advisory Committees Approval Process Pharmaceuticals Regulatory Approval Vaccine Advocacy Vaccine Approval Process Variants Pharmacy Services Vaccine Misinformation Recommendations HIV Approval Standards mRNA Vaccines Co-administration of Vaccines Nuvaxovid Vaccine Market RSV Vaccines Side Effects Regulations Access 2025-2026 Vaccines Spikevax SARS-CoV-2 Variants Public Health Procurement Treatment Regulatory Guidance Vaccine Efficacy Vaccine Skepticism Children and Pregnant Women Immunogenicity Data Licensure Vaccine Advisory Panels

FDA Advisers Recommend XFG as Target for 2026–2027 COVID-19 Vaccines

The recommendation steers fall vaccine production toward XFG to boost protection against the currently dominant JN.1-family strains.

Moderna Beats Q1 Forecast as Overseas COVID Shot Sales Rebound

Pfizer and BioNTech Halt U.S. COVID Vaccine Trial for 50–64-Year-Olds Over Slow Enrollment

Moderna Trims 2025 Forecast as Q3 Loss Narrows and Revenue Beats

States Restore Broad COVID-19 Shot Access as Pharmacies Roll Out Patchwork Policies

Pharmacies Curtail Covid Vaccines in 16 States as Confusion Over Federal Guidance Disrupts Access

Greene Urges DOJ to Drop Charges Against Surgeon on Trial for COVID-19 Vaccine Fraud

FDA Approves Moderna’s mNEXSPIKE for High-Risk Populations